Anti-aggregation agent, and pharmaceutical composition and medical device using same
A technology of aggregating agent and composition, which can be used in drug combinations, pharmaceutical formulations, medical preparations of inactive ingredients, etc., and can solve problems such as difficulty in aggregation
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0075] (Example 1: Test suspension containing aripiprazole)
Embodiment 1-1-1
[0076] (Example 1-1-1: Preparation and evaluation of test suspension using polyoxyethylene cetyl ether)
[0077] Aripiprazole hydrate, sodium carboxymethyl cellulose, mannitol, and sodium dihydrogen phosphate monohydrate, which are poorly water-soluble drugs, were added to purified water to achieve the following concentrations to prepare an aripiprazole suspension.
[0078] ・Aripiprazole hydrate: 30% by mass (as anhydrous);
[0079] ・Sodium carboxymethylcellulose: about 1.248% by mass;
[0080] ・Mannitol: about 6.24% by mass;
[0081] ・Sodium dihydrogen phosphate monohydrate: about 0.111% by mass.
[0082] To 1 g of the aripiprazole suspension, only an amount equivalent to 4 parts by mass of polyoxyethylene cetyl ether was added as an anti-aggregation agent with respect to 100 parts by mass of aripiprazole contained in the suspension, and the Stir. To the suspension was added 1% silicone oil emulsion (Dow Corning (registered trademark) 365, 35% dimethicone NF Elusion; here...
Embodiment 1-1-2~1-1-7
[0083] (Examples 1-1-2 to 1-1-7: Preparation and evaluation of test suspensions using polyoxyethylene cetyl ether)
[0084] To the test suspension (E1-1-1) (suspension before ultrasonic treatment) obtained in Example 1-1-1, 1% of silicone oil emulsion was added, respectively, so that the silicone oil contained in the suspension was adjusted to 100% by mass. Part of aripiprazole was in the amount shown in Table 1, and the test suspensions (E1-1-2) to (E1-1-7) were prepared to obtain the test suspensions (E1-1-2) to (E1 -1-7). The particle sizes of particles contained in the test suspensions before (a) and after (b) ultrasonication were measured for each test suspension. The results are shown in Table 1.
PUM
![No PUM](https://static-eureka-patsnap-com.libproxy1.nus.edu.sg/ssr/23.2.0/_nuxt/noPUMSmall.5c5f49c7.png)
Abstract
Description
Claims
Application Information
![application no application](https://static-eureka-patsnap-com.libproxy1.nus.edu.sg/ssr/23.2.0/_nuxt/application.06fe782c.png)
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com